JP2019534044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534044A5 JP2019534044A5 JP2019545717A JP2019545717A JP2019534044A5 JP 2019534044 A5 JP2019534044 A5 JP 2019534044A5 JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019534044 A5 JP2019534044 A5 JP 2019534044A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022087695A JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419157P | 2016-11-08 | 2016-11-08 | |
| US62/419,157 | 2016-11-08 | ||
| PCT/US2017/060122 WO2018089293A2 (en) | 2016-11-08 | 2017-11-06 | Anti-pd1 and anti-ctla4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022087695A Division JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534044A JP2019534044A (ja) | 2019-11-28 |
| JP2019534044A5 true JP2019534044A5 (enExample) | 2021-02-12 |
Family
ID=60409406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545717A Pending JP2019534044A (ja) | 2016-11-08 | 2017-11-06 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
| JP2022087695A Active JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022087695A Active JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11124570B2 (enExample) |
| EP (1) | EP3538137A2 (enExample) |
| JP (2) | JP2019534044A (enExample) |
| CN (2) | CN118480125A (enExample) |
| AU (1) | AU2017356860A1 (enExample) |
| CA (1) | CA3042249A1 (enExample) |
| WO (1) | WO2018089293A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475627B (zh) | 2016-05-26 | 2023-01-06 | 齐鲁普吉湾生物治疗公司 | 抗体混合物 |
| CN118480125A (zh) | 2016-11-08 | 2024-08-13 | 齐鲁皮吉特湾生物治疗有限公司 | 抗pd1和抗ctla4抗体 |
| BR112021012630A2 (pt) * | 2018-12-28 | 2022-12-13 | Transgene Sa | Poxvírus modificado, método para produzir o poxvírus modificado e composição |
| US20220235144A1 (en) * | 2019-03-04 | 2022-07-28 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| EP4021579A1 (en) | 2019-08-30 | 2022-07-06 | Qilu Puget Sound Biotherapeutics Corporation | Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof |
| CN115515973B (zh) * | 2020-05-06 | 2025-12-12 | 高丽大学校产学协力团 | 增加pd-l1亲和度的pd-1变异体 |
| CN111875697B (zh) * | 2020-08-03 | 2021-10-01 | 杭州皓阳生物技术有限公司 | 一种包含肽标签的融合蛋白 |
| US20220267446A1 (en) * | 2021-02-18 | 2022-08-25 | Qilu Puget Sound Biotherapeutics Corporation | Combinations of anti-pd1 and anti-ctla4 antibodies |
| CN118660720A (zh) * | 2022-02-22 | 2024-09-17 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2023185720A1 (zh) * | 2022-03-28 | 2023-10-05 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2023198089A1 (zh) * | 2022-04-13 | 2023-10-19 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2023240086A1 (en) * | 2022-06-07 | 2023-12-14 | Unm Rainforest Innovations | Humanized non-opioid composition and therapies for pain management |
| US20250376525A1 (en) * | 2022-06-28 | 2025-12-11 | Qilu Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |
| WO2024002226A1 (zh) * | 2022-06-30 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2025113598A1 (zh) * | 2023-12-01 | 2025-06-05 | 齐鲁制药有限公司 | 稳定的混合抗体的药物组合物 |
| WO2025228542A1 (en) | 2024-05-03 | 2025-11-06 | Genmab B.V. | Method for co-expression of a plurality of antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU670075B2 (en) | 1992-02-26 | 1996-07-04 | Allergan, Inc. | Use of platelet derived growth factor in ophthalmic wound healing |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| SI2112166T1 (sl) | 1998-12-23 | 2019-05-31 | Pfizer Inc. | Človeška monoklonska protitelesa proti CTLA-4 |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| CN1371416B (zh) * | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| KR20110013423A (ko) * | 2008-05-29 | 2011-02-09 | 브리스톨-마이어스 스큅 컴퍼니 | 보조자극 경로의 조절에 대한 환자 반응을 예측하는 방법 |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| WO2011045704A1 (en) * | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| AU2011317743B2 (en) | 2010-10-18 | 2015-05-21 | Mediapharma S.R.L. | ErbB3 binding antibody |
| WO2012123949A1 (en) | 2011-03-17 | 2012-09-20 | Ramot At Tel-Aviv University Ltd. | Bi- and monospecific, asymmetric antibodies and methods of generating the same |
| CN202105787U (zh) | 2011-06-03 | 2012-01-11 | 杨自强 | 糠粞分离机 |
| BR122022000334B1 (pt) | 2011-08-01 | 2023-03-21 | Genentech, Inc | Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek |
| CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP3486255A3 (en) | 2013-03-13 | 2019-11-13 | Ibentrus Inc. | Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor |
| PL3081576T3 (pl) * | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US10954301B2 (en) * | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| CN118480125A (zh) | 2016-11-08 | 2024-08-13 | 齐鲁皮吉特湾生物治疗有限公司 | 抗pd1和抗ctla4抗体 |
-
2017
- 2017-11-06 CN CN202410423333.9A patent/CN118480125A/zh active Pending
- 2017-11-06 US US16/347,554 patent/US11124570B2/en active Active
- 2017-11-06 CN CN201780069181.5A patent/CN110312523B/zh active Active
- 2017-11-06 CA CA3042249A patent/CA3042249A1/en active Pending
- 2017-11-06 WO PCT/US2017/060122 patent/WO2018089293A2/en not_active Ceased
- 2017-11-06 EP EP17801203.5A patent/EP3538137A2/en active Pending
- 2017-11-06 AU AU2017356860A patent/AU2017356860A1/en not_active Abandoned
- 2017-11-06 JP JP2019545717A patent/JP2019534044A/ja active Pending
-
2021
- 2021-09-16 US US17/477,525 patent/US12037397B2/en active Active
-
2022
- 2022-05-30 JP JP2022087695A patent/JP7455897B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534044A5 (enExample) | ||
| ES2777603T3 (es) | Anticuerpos PD-L1 ("ligando de muerte programada 1") | |
| JP2020516240A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2017532952A5 (enExample) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
| RU2019104980A (ru) | Анти-icos антитела | |
| CN102753195A (zh) | 用于增强抗肿瘤抗体疗法的方法 | |
| JP2018532383A5 (enExample) | ||
| JP2019528683A5 (enExample) | ||
| CN111183159A (zh) | 靶向cd137的抗体及其使用方法 | |
| JP2025065211A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| AU2020207664A1 (en) | Antibodies specific to human Nectin-2 | |
| CN113412124A (zh) | Baff-r双特异性t细胞衔接子抗体 | |
| JPWO2019165340A5 (enExample) | ||
| CN113501879B (zh) | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 | |
| IL277899B1 (en) | Methods and compositions for treating yellow fever | |
| CA3062479A1 (en) | Bispecific recombinant protein and use thereof | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| JPWO2020144697A5 (enExample) | ||
| AU2015271978B2 (en) | Treatment for neoplastic diseases | |
| RU2020133629A (ru) | Антитела, специфичные к нектину-4 человека |